greeksoup/ stock research
Stock research / United States / IBRX / Documents

ImmunityBio, Inc. documents

ImmunityBio (IBRX) annual report: the 10-K filed 23 February 2026 for the year ended 31 December 2025. Proxy statement (DEF 14A) filed 30 April 2026; latest 10-Q filed 4 August 2026 for the quarter ended 30 June 2026. Each links to the document on EDGAR, with 6 earnings press releases.

Earnings press releases (exhibit 99 to each results 8-K)

FiledDocumentOpenWhere
4 August 2026Results press release, exhibit 99 to the 8-K filed 4 August 2026The releaseEDGAR folder
7 May 2026Results press release, exhibit 99 to the 8-K filed 7 May 2026The releaseEDGAR folder
9 April 2026Results press release, exhibit 99 to the 8-K filed 9 April 2026The releaseEDGAR folder
23 February 2026Results press release, exhibit 99 to the 8-K filed 23 February 2026The releaseEDGAR folder
15 January 2026Results press release, exhibit 99 to the 8-K filed 15 January 2026The releaseEDGAR folder
5 November 2025Results press release, exhibit 99 to the 8-K filed 5 November 2025The releaseEDGAR folder

Annual reports (10-K)

FiledDocumentOpenWhere
23 February 202610-K, period ended 31 December 2025The documentEDGAR folder

Quarterly reports (10-Q)

FiledDocumentOpenWhere
4 August 202610-Q, period ended 30 June 2026The documentEDGAR folder
7 May 202610-Q, period ended 31 March 2026The documentEDGAR folder
5 November 202510-Q, period ended 30 September 2025The documentEDGAR folder

Proxy statements

FiledDocumentOpenWhere
30 April 2026DEF 14A, period ended 9 June 2026The documentEDGAR folder

Annual report to shareholders

FiledDocumentOpenWhere
30 April 2026ARS, period ended 31 December 2025The documentEDGAR folder